Crucell Signs Agreement with IAVI to Develop AdVac® Vector for AIDS Vaccine Program

16-Nov-2004

Dutch biotechnology company Crucell N.V. and the International AIDS Vaccine Initiative (IAVI) have signed an agreement whereby Crucell will develop AdVac® vectors for use in IAVI's AIDS vaccine development program. Financial details were not disclosed.

Earlier this year Crucell and IAVI entered into an exclusive license agreement to develop an AIDS vaccine based on Crucell's AdVac® technology.

The AdVac® vectors, adenovirus serotypes 11 and 35, have shown promising results as vectors for AIDS vaccines in a series of studies by Crucell in collaboration with Harvard Medical School. AdVac® technology is also being applied by Crucell in the production of a malaria vaccine in collaboration with GlaxoSmithKline, Walter Reed Army Institute of Research and the National Institute of Allergy and Infectious Diseases of the NIH, as well as a TB vaccine in collaboration with the Aeras Global TB Vaccine Foundation.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances